Oxurion Reaches Enrollment Target in KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema

This document constitutes regulated information in the sense of the Royal Decree of 14 November 2007 and/or the Law of 2 August 2002. For the full press release, download the PDF document(s) above.